Ronit Mazor, Ph.D. - Postdoctoral Fellow, National Cancer Institute, NIH
Recombinant immunotoxins are potent fusion proteins that specifically kill tumor cells. Their efficacy in hindered by their inherent immunogenicity. Here we show two approaches to reduce the immunogenicity of a therapeutic protein. The first describes rational analysis and design of human and murine T cell epitopes using experimental and computational approaches. The second approach includes induction of specific immune tolerance that resulted in restoration of the neutralized anti-tumor activity.